SEARCH

SEARCH BY CITATION

References

  • Abare JM, Worthen DM, Floyd BB & Cleveland PH (1985): Detection of fibronectin, laminin, collagens type IV and VI in the trabecular meshwork of normals and patients with glaucoma. ARVO Abstract. Invest Ophthalmol Vis Sci 26: 111.
  • Acott TS (1992): Trabecular extracellular matrix regulation. In: DranceSM, Van BuskirkEM & NeufeldAH (eds). Pharmacology of Glaucoma. Baltimore: Williams & Wilkins; 125157.
  • Alexander J & Acott TS (2003): Involvement of the Erk-MAP kinase pathway in TNFα regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci 44: 164169.DOI: 10.1167/iovs.01-1201
  • Alexander JP, Samples JR & Acott TS (1998): Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res 17: 276285.DOI: 10.1076/ceyr.17.3.276.5219
  • Alexander JP, Samples JR, Van Buskirk EM & Acott TS (1991): Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 32/1: 172180.
  • Alvarado J, Murphy C & Juster R (1984): Trabecular meshwork cellularity in primary open-angle glaucoma and non-glaucomatous normals. Ophthalmology 91: 564.
  • Babizhayev MA & Brodskaya MW (1989): Fibronectin detection in drainage outflow system of human ageing and progression of open-angle glaucoma. Mech Ageing Dev 47: 145157.
  • Bradley JM, Anderssohn AM, Colvis CM, Parshley DE, Zhu XH, Ruddat MS, Samples JR & Acott TS (2000): Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1β and TNFα. Invest Ophthalmol Vis Sci 41: 422430.
  • Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS, Samples JR & Acott TS (1998): Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci 39: 26492658.
  • Di Girolamo N, Verma MJ, McCluskey MJ, Lloyd A & Wakefield D (1996): Increased matrix metalloproteinases in the aqueous humour of patients and experimental animals with uveitis. Curr Eye Res 15: 10601068.
  • Ehrich D, Tripathi B, Tripathi R & Dunker G (2001): Increased hydrostatic pressure influences expression of matrix metalloproteases mRNAs by trabecular cells. Res Com Pharm Toxic 6 (1, 2): 107116.
  • Frisch SM & Ruley HE (1987): Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone. J Biol Chem 262: 1630016304.
  • Gasull X, Ferrer E, Llobet A, Castellano A, Nicolas JM, Pales J & Gual A (2003): Cell membrane stretch modulates the high conductance Ca2+-activated K+ channel in bovine trabecular meshwork cells. Invest Ophthalmol Vis Sci 44: 706714.
  • Gaton DD, Sagara T, Lindsey JD & Weinreb RN (1999): Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway. Invest Ophthalmol Vis Sci 40: 363369.
  • Goettlicher M, Heck S & Herrlich P (1998): Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 76: 480489.
  • Gong H & Fredo TF (1994): Hyaluronic acid in the normal and glaucomatous human outflow pathway. Invest Ophthalmol Vis Sci 35: 2083.
  • Gonzalez-Avila G, Ginebra M, Hayakawa T, Vadillo-Ortega F, Teran L & Selman M (1995): Collagen metabolism in human aqueous humour from primary open-angle glaucoma. Decreased degradation and increased biosynthesis play a role in its pathogenesis. Arch Ophthalmol 113: 13191323.
  • Hungness ES, Pritts TA, Luo GJ, Sun X, Penner CG & Hasselgren PO (2000): The transcription factor activator protein-1 is activated and interleukin-6 production is increased in interleukin-1β-stimulated human enterocytes. Shock 14: 386391.
  • Jonat C, Rahmsdorf HJ, Park KK et al. (1990): Anti-tumour promotion and anti-inflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62: 11891204.
  • Kee C & Seo K (1997): The effect of interleukin-1α on outflow facility in rat eyes. J Glaucoma 6: 246249.
  • Knepper PA, Goossens W, Hvizd M & Palmberg PF (1996): Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 37: 13601367.
  • Luetjen-Drecoll E, Rittig M, Rauterberg R, Jander R & Mollenhauer J (1989): Immunohistochemical study of type VI collagen in the trabecular meshwork of normal and glaucomatous eyes. Exp Eye Res 48: 139147.
  • Murphy G, Cockett MI, Ward RV & Docherty AJ (1991): Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysin-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277: 277279.
  • Nagase H (1998): Stromelysins 1 and 2. In: ParksWC & MechamRP (eds). Matrix Metalloproteinases. San Diego: Academic Press. 4384.
  • Nagase H, Meng Q, Malinovski V, Huang W, Chung L, Bode W, Maskos K & Brew K (1999): Engineering of selective TIMPs. Ann N Y Acad Sci 878: 111.
  • Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M & Okada Y (1997): Membrane type I matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biochem 272: 24462451.
  • Pang IH, Shade DL & Clark AF (2000): Involvement of activation protein-1 (AP-1) in interleukin-1α (IL-1α)-induced stimulation of stromelysin (MMP-3) expression in cultured human trabecular meshwork (TM) cells. ARVO Abstract 41 (4).
  • Parshley DE, Bradley JM, Fisk A, Hadaegh A, Samples JR, Van Buskirk EM & Acott TS (1996): Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells. Invest Ophthalmol Vis Sci 37: 795804.
  • Parshley DE, Bradley JM, Samples JR, Van Buskirk EM & Acott TS (1995): Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res 14: 537544.
  • Rodriques MM, Spaeth GL, Sivalingam E & Weinreb S (1976): Histopathology of 150 trabeculectomy specimens in glaucoma. Trans Ophthalmol Soc U K 96: 245.
  • Rohen J & Luetjen-Drecoll E (1989): Morphology of aqueous outflow pathways in normal and glaucomatous eyes. In: RitchR, ShieldsMB & KrupinT (eds). The Glaucomas. St. Louis, Missouri: CV Mosby; 89124.
  • Samples JR, Alexander JP & Acott TS (1993): Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by IL-1 and dexamethasone. Invest Ophthalmol Vis Sci 34/12: 33863395.
  • Samples JR, Brown-Istvan L & Snyder AA (1998): Interleukin-1α-transforming growth factor-β interactions in trabecular meshwork stromelysin production. ARVO Abstract 39 (4).
  • Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AGP & Naumann GOH (2003): Matrix metalloproteinases and their inhibitors in aqueous humour of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 44: 11171125.
  • Snyder RW, Stamer WD, Kramer TR & Seftor RE (1993): Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernats. Exp Eye Res 57: 461468.
  • Tripathi BJ, Li T, Li J, Tran L & Tripathi RC (1996): Age-related changes in trabecular cells in vitro. Exp Eye Res 64: 5766.
  • Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y & Chalam KV (1999): Corticosteroids and glaucoma risk. Drugs Aging 15: 439450.
  • Tripathi RC, Park JK, Tripathi BJ & Ts'ao C (1989): Tissue plasminogen activator synthesis by trabecular cells and its implications for fibrinolytic therapy of the eye. Drug Dev Res 18: 245254.
  • Wirtz MK, Bradley JM, Xu H et al. (1997): Proteoglycan expression by human trabecular meshworks. Curr Eye Res 16: 412421.
  • Yu AE, Murphy AN & Stedtler-Stevenson WG (1998): 72-kDa gelatinase (gelatinase A): structure, activation, regulation and substrate specificity. In: ParksWC & MechamRP (eds). Matrix Metalloproteinases. (Biology of the Extracellular Matrix). San Diego: Academic Press; 85113.